Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use
Author: Proudman, S.
Keen, H.
Stamp, L.
Lee, A.
Goldblatt, F.
Ayres, O.
Rischmueller, M.
James, M.
Hill, C.
Caughey, G.
Cleland, L.
Citation: Seminars in Arthritis and Rheumatism, 2007; 37(2):99-111
Publisher: W B Saunders Co
Issue Date: 2007
ISSN: 0049-0172
Statement of
Susanna M. Proudman, Helen I. Keen, Lisa K. Stamp, Anita T.Y. Lee, Fiona Goldblatt, Oliver C. Ayres, Maureen Rischmueller, Michael J. James, Catherine L. Hill, Gillian E. Caughey and Leslie G. Cleland
Abstract: <h4>Objectives</h4>To assess the safety and efficacy of combination therapy in recent-onset rheumatoid arthritis (RA), with dose adjustments determined by response, in a clinic setting over 3 years.<h4>Methods</h4>Disease-modifying antirheumatic drug (DMARD)-naive patients with RA of median duration of 12 weeks (n = 61) attending an early arthritis clinic were treated with methotrexate, sulfasalazine, hydroxychloroquine, and fish oil. Dosage adjustments and additions of further DMARDs were contingent on response to therapy and tolerance. Outcome measures for efficacy were Disease Activity Score (DAS28), clinical remission, and modified Sharp radiographic score and for safety, adverse events, and DMARD withdrawal.<h4>Results</h4>At baseline, subjects had at least moderately active disease (mean +/- SD DAS28 was 5.3 +/- 1.1), impaired function as measured by the modified Health Assessment Questionnaire (mHAQ) (0.9 +/- 0.5), and 37% had bone erosions. By 3 months, 29% were in remission; this increased to 54% at 3 years. The greatest fall in DAS28 and improvement in mHAQ scores occurred in the first 12 months. Erosions were detected in 62% at 3 years. The mean dose of parenteral glucocorticoid was equivalent to 0.1 mg/d of prednisolone. After 3 years, 48% remained on triple therapy; fish oil was consumed by 75% of patients, and 21% used nonsteroidal anti-inflammatory drugs. Gastrointestinal intolerance was the most frequent unwanted event (leading to DMARD withdrawal in 17 patients). Sulfasalazine was most frequently withdrawn (30%).<h4>Conclusion</h4>This implementation study demonstrates the feasibility, safety, and efficacy of combination therapy with inexpensive DMARDs, fish oil, and minimal glucocorticoid use, in routine clinical practice using predefined rules for dosage adjustment.
Keywords: Humans; Arthritis, Rheumatoid; Sulfasalazine; Methotrexate; Hydroxychloroquine; Fish Oils; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Glucocorticoids; Treatment Outcome; Drug Therapy, Combination; Severity of Illness Index; Longitudinal Studies; Dose-Response Relationship, Drug; Adult; Aged; Middle Aged; Female; Male; Outcome Assessment, Health Care
Description: Copyright © 2007 Elsevier Inc. All rights reserved.
RMID: 0020073232
DOI: 10.1016/j.semarthrit.2007.02.001
Description (link):
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.